专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US11104733B2 PD-1 immune modulating agents 有权
公开(公告)号：US11104733B2
公开(公告)日：2021-08-31
申请号：US15849107
申请日：2017-12-20
申请人： MEMORIAL SLOAN-KETTERING CANCER CENTER , EUREKA THERAPEUTICS, INC.
发明人： Renier J. Brentjens , Hollie Jaine Jackson , Cheng Liu
IPC分类号： C07K16/28 , A61K39/395 , A61K35/17 , A61K48/00 , C07K14/705 , C07K14/725 , A61K47/68 , A61P35/00 , C07K16/30 , A61K39/00 , A61K38/00 , A61K35/12
摘要： The present application provides anti-PD-1 antigen-binding proteins or a fragment thereof, as well as nucleic acids encoding anti-PD-1 antigen-binding proteins or CAR T cells expressing such antigen-binding protein or fragment. Also provided are methods of regulating T cells or treating patients using such constructs or cells.

2. 发明授权

US10918665B2 Chimeric antigen receptors targeting B-cell maturation antigen and uses thereof 有权
公开(公告)号：US10918665B2
公开(公告)日：2021-02-16
申请号：US15613638
申请日：2017-06-05
申请人： MEMORIAL SLOAN KETTERING CANCER CENTER , EUREKA THERAPEUTICS, INC.
发明人： Renier J. Brentjens , Eric L. Smith , Cheng Liu
IPC分类号： A61K35/17 , C07K16/28 , C07K14/725 , C07K14/705 , A61P35/00
摘要： The presently disclosed subject matter provides for methods and compositions for treating multiple myeloma. It relates to chimeric antigen receptors (CARs) that specifically target B cell maturation antigen (BMCA), and immunoresponsive cells comprising such CARs. The presently disclosed BMCA-specific CARs have enhanced immune-activating properties, including anti-tumor activity.

3. 发明授权

US10913796B2 Antibodies targeting Fc receptor-like 5 and methods of use 有权
公开(公告)号：US10913796B2
公开(公告)日：2021-02-09
申请号：US15997155
申请日：2018-06-04
申请人： MEMORIAL SLOAN-KETTERING CANCER CENTER , EUREKA THERAPEUTICS, INC.
发明人： Renier J. Brentjens , Eric L. Smith , Cheng Liu
IPC分类号： C07K16/00 , C12P21/08 , A61K39/395 , A61K39/40 , A61K39/00 , C07K16/28 , A61K47/64 , A61K47/68 , A61P35/00
摘要： The presently disclosed subject matter provides fully human antibodies or antigen-binding fragments thereof that bind to FcRL5 and methods of using the same.

4. 发明申请

US20200276239A1 METHODS OF USING CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN AND USES THEREOF 审中-公开
公开(公告)号：US20200276239A1
公开(公告)日：2020-09-03
申请号：US16844610
申请日：2020-04-09
申请人： MEMORIAL SLOAN KETTERING CANCER CENTER , EUREKA THERAPEUTICS, INC.
发明人： Renier J. Brentjens , Eric L. Smith , Cheng Liu
IPC分类号： A61K35/17 , C07K16/28 , C07K14/725 , C07K14/705 , A61P35/00
摘要： The presently disclosed subject matter provides for methods and compositions for treating multiple myeloma. It relates to chimeric antigen receptors (CARs) that specifically target B cell maturation antigen (BMCA), and immunoresponsive cells comprising such CARs. The presently disclosed BMCA-specific CARs have enhanced immune-activating properties, including anti-tumor activity.

5. 发明授权

US10562972B2 Antibodies targeting B-cell maturation antigen and methods of use 有权
公开(公告)号：US10562972B2
公开(公告)日：2020-02-18
申请号：US15613986
申请日：2017-06-05
申请人： MEMORIAL SLOAN KETTERING CANCER CENTER , EUREKA THERAPEUTICS, INC.
发明人： Renier J. Brentjens , Eric L. Smith , Cheng Liu
IPC分类号： A61K39/395 , C07K16/28 , A61K47/68 , A61P35/00 , G01N33/68
摘要： The presently disclosed subject matter provides antibodies that bind to B-cell maturation antigen (BCMA) and methods of using the same.

6. 发明申请

US20170088630A1 T CELL RECEPTOR-LIKE ANTIBODIES SPECIFIC FOR A WTI PEPTIDE PRESENTED BY HLA-A2 审中-公开
公开(公告)号：US20170088630A1
公开(公告)日：2017-03-30
申请号：US15364953
申请日：2016-11-30
申请人： MEMORIAL SLOAN KETTERING CANCER CENTER , EUREKA THERAPEUTICS, INC.
发明人： David Scheinberg , Tao Dao , Cheng Liu , Su Yan
IPC分类号： C07K16/32 , A61K47/48 , C07K16/28 , G01N33/574
CPC分类号： C07K16/32 , A61K47/6849 , A61K47/6851 , A61K2039/505 , C07K16/18 , C07K16/2833 , C07K2317/21 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/732 , G01N33/5748
摘要： The present invention provides antigen binding proteins that specifically bind to Wilms' tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of WT1 associated cancers, including for example, breast cancer, ovarian cancer, prostate cancer, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). In more particular embodiments, the anti-WT1/A antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels.

7. 发明申请

US20160280796A1 ANTI-WT1/HLA BI-SPECIFIC ANTIBODY 审中-公开
标题翻译： ANTI-WT1 / HLA BI特异性抗体
公开(公告)号：US20160280796A1
公开(公告)日：2016-09-29
申请号：US15034782
申请日：2014-11-07
申请人： MEMORIAL SLOAN-KETTERING CANCER CENTER , EUREKA THERAPEUTICS, INC.
发明人： David Scheinberg , Jingyi Xiang , Tao Dao , Su Yan , Cheng Liu
IPC分类号： C07K16/32 , C07K16/28
CPC分类号： C07K16/32 , A61K2039/505 , C07K16/2809 , C07K2317/31 , C07K2317/34 , C07K2317/622 , C07K2317/73
摘要： Disclosed herein is a bi-specific form of a T cell receptor mimic (TCRm) mAb with reactivity to human immune effector cell antigen and a WT1 peptide/HLA-A epitope. This antibody selectively bound to leukemias and solid tumor cells expressing WT1 and HLA-A as well as activated resting human T cells to release interferon-(IFN-γ) and to kill the target cancer cells in vitro. Importantly, the antibody mediated autologous T cell proliferation and directed potent cytotoxicity against fresh ovarian cancer cells. Therapeutic activity in vivo of the antibody was demonstrated in NOD SCID SCID Yc* (NSG) mice with three different human cancers expressing WT1/HLA-A2 including disseminated Ph+ acute lymphocytic leukemia (ALL), disseminated acute myeloid leukemia, and peritoneal mesothelioma. In both of the leukemia xenograft models, mice that received the antibody and T cells also showed longer survival and delayed limb paralysis. Also provided are methods for stimulating a primary T cell response comprising stimulating cytotoxic T cells against a first tumor antigen and a secondary T cell response comprising stimulating effector T cells and/or memory T cells against a first tumor antigen and/or against a second tumor antigen using the bi-specific antibodies described herein.
摘要翻译：本文公开了与人免疫效应细胞抗原和WT1肽/ HLA-A表位具有反应性的T细胞受体模拟物（TCRm）mAb的双特异性形式。该抗体选择性结合表达WT1和HLA-A的白血病和实体肿瘤细胞以及活化的休息的人T细胞以释放干扰素（IFN-γ）并在体外杀死靶癌细胞。重要的是，抗体介导的自体T细胞增殖和对新鲜卵巢癌细胞的有力的细胞毒性。在具有表达WT1 / HLA-A2的三种不同人类癌症的NOD SCID SCID Yc *（NSG）小鼠中证实了抗体的治疗活性，包括播散性Ph +急性淋巴细胞性白血病（ALL），弥散性急性骨髓性白血病和腹膜间皮瘤。在两种白血病异种移植模型中，接受抗体和T细胞的小鼠也显示较长的存活期和延迟的肢体麻痹。还提供了用于刺激原代T细胞应答的方法，包括刺激针对第一肿瘤抗原的细胞毒性T细胞和辅助T细胞应答，包括针对第一肿瘤抗原和/或针对第二肿瘤刺激效应T细胞和/或记忆T细胞使用本文所述的双特异性抗体。

8. 发明申请

US20210346432A1 METHODS OF USING CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN AND USES THEREOF 有权
公开(公告)号：US20210346432A1
公开(公告)日：2021-11-11
申请号：US17228213
申请日：2021-04-12
申请人： MEMORIAL SLOAN KETTERING CANCER CENTER , EUREKA THERAPEUTICS, INC.
发明人： Renier J. Brentjens , Eric L. Smith , Cheng Liu
IPC分类号： A61K35/17 , C07K16/28 , C07K14/705 , C07K14/725 , A61P35/00
摘要： The presently disclosed subject matter provides for methods and compositions for treating multiple myeloma. It relates to chimeric antigen receptors (CARs) that specifically target B cell maturation antigen (BCMA), and immunoresponsive cells comprising such CARs. The presently disclosed BCMA-specific CARs have enhanced immune-activating properties, including anti-tumor activity.

9. 发明授权

US11136392B2 PD-1 immune modulating agents 有权
公开(公告)号：US11136392B2
公开(公告)日：2021-10-05
申请号：US15849107
申请日：2017-12-20
申请人： MEMORIAL SLOAN-KETTERING CANCER CENTER , EUREKA THERAPEUTICS, INC.
发明人： Renier J. Brentjens , Hollie Jaine Jackson , Cheng Liu
IPC分类号： C07K16/28 , A61K39/395 , A61K35/17 , A61K48/00 , C07K14/705 , C07K14/725 , A61K47/68 , A61P35/00 , C07K16/30 , A61K39/00 , A61K38/00 , A61K35/12
摘要： The present application provides anti-PD-1 antigen-binding proteins or a fragment thereof, as well as nucleic acids encoding anti-PD-1 antigen-binding proteins or CAR T cells expressing such antigen-binding protein or fragment. Also provided are methods of regulating T cells or treating patients using such constructs or cells.

10. 发明授权

US11117964B2 Anti-KIR3DL1 antibodies 有权
公开(公告)号：US11117964B2
公开(公告)日：2021-09-14
申请号：US16484451
申请日：2018-02-26
申请人： Memorial Sloan Kettering Cancer Center , Eureka Therapeutics, Inc.
发明人： Katharine Hsu , Nai-Kong V. Cheung , Su Yan , Yiyang Xu , Jingyi Xiang , Cheng Liu
IPC分类号： C07K16/28 , A61K39/295 , A61P35/02 , G01N33/53 , C12N5/10 , C12N15/63 , C12N15/11 , A61K47/68 , A61K39/395 , A61K45/06 , C07K14/705
摘要： The disclosure provides antibody agents that bind to inhibitory human killer immunoglobulin-like receptors (KIRs). Particular antibody agents of the disclosure include antibody agents that bind to KIR3DL1 (also known as CD158e). Also provided are related nucleic acids, vectors, compositions and methods of using KIR-binding antibody agents of the present technology.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式